Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Clinical trial NCT02113007 · TERMINATED
Trial details
- NCT number
- NCT02113007
- Sponsor
- SCRI Development Innovations, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2016-02-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.